We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+275.57%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
+$7.44M
Cap. Flow %
5.12%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 48.9%
2 Financials 13.82%
3 Miscellaneous 11.7%
4 Technology 6.61%
5 Consumer Discretionary 5.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRNA icon
151
Moderna
MRNA
$58.1B
$118K 0.08%
+4,583
New +$128K
TNYA icon
152
Tenaya Therapeutics
TNYA
$153M
$117K 0.08%
+72,494
New +$73K
AYTU icon
153
AYTU BioPharma
AYTU
$23.7M
$117K 0.08%
+62,452
New +$144K
OLMA icon
154
CALL
Olema Pharmaceuticals
OLMA
$941M
$116K 0.08%
+209
New +$1.25K
MNKD icon
155
CALL
MannKind Corp
MNKD
$1.31B
$115K 0.08%
2,393
+1,196
+100% +$5.25K
MRNA icon
156
PUT
Moderna
MRNA
$58.1B
$108K 0.07%
230
-45,252
-99% -$1.26M
AVR
157
Anteris Technologies
AVR
$881M
$105K 0.07%
23,317
C icon
158
CALL
Citigroup
C
$231B
$102K 0.07%
+151
New +$14.3K
VNET
159
VNET Group
VNET
$1.81B
$99.7K 0.07%
+9,651
New +$81.3K
AS icon
160
Amer Sports
AS
$17.2B
$99K 0.07%
+2,849
New +$107K
EQ icon
161
Equillium
EQ
$140M
$98.7K 0.07%
+68,991
New +$73K
ALEC icon
162
Alector
ALEC
$275M
$92.5K 0.06%
31,240
-29,856
-49% -$65.8K
JAZZ icon
163
CALL
Jazz Pharmaceuticals
JAZZ
$16B
$89.2K 0.06%
229
+114
+99% +$13.7K
SKYE icon
164
CALL
Skye Bioscience
SKYE
$8.24M
$80.8K 0.06%
+86
New +$2.6K
PRQR icon
165
ProQR Therapeutics
PRQR
$292M
$77.3K 0.05%
36,280
PYXS icon
166
Pyxis Oncology
PYXS
$324M
$76.9K 0.05%
+34,632
New +$49.9K
CAPR icon
167
CALL
Capricor Therapeutics
CAPR
$547M
$72.6K 0.05%
+689
New +$5.07K
MBX
168
CALL
MBX Biosciences
MBX
$2.97B
$71.8K 0.05%
+230
New +$3.08K
KOD icon
169
CALL
Kodiak Sciences
KOD
$2.22B
$68.5K 0.05%
+64
New +$552
PTHS
170
Pelthos Therapeutics
PTHS
$93.2M
$67.3K 0.05%
+2,403
New +$58.3K
RARE icon
171
Ultragenyx Pharmaceutical
RARE
$1.51B
$62.6K 0.04%
2,082
-10,355
-83% -$311K
OVID icon
172
Ovid Therapeutics
OVID
$547M
$59.9K 0.04%
+46,040
New +$39.9K
RARE icon
173
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
$59.5K 0.04%
347
-153
-31% -$4.59K
NEUP
174
Neuphoria Therapeutics
NEUP
$20.4M
$57.9K 0.04%
+4,908
New +$45.6K
CLYM
175
Climb Bio
CLYM
$891M
$56.7K 0.04%
28,221
-116,958
-81% -$217K

Similar funds

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners deployed $7.44M of net new capital in Q3 2025, opening 137 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 229,544 shares worth $8.19M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was iShares Bitcoin Trust, an estimated $3.43M trimmed.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.